ODINSIGNAL JOURNAL · NEWS & EVENTS
FDA decision on ulixacaltamide for essential tremor set for Jan 29 2027
Praxis Precision Medicines' ulixacaltamide has a FDA PDUFA target action date of Jan 29 2027 for essential tremor. Follow the upcoming decision on OdinSignal.
At a glance
- Date
- Jan 29
- Participants
- PRAX
Praxis Precision Medicines’ experimental drug ulixacaltamide is under FDA review for essential tremor. The PDUFA target action date listed in the BioRadar calendar is Jan 29 2027 for the ulixacaltamide NDA【BioRadar PDUFA calendar】. The decision will be binary – approval, a complete response letter, or an extension – and will be a key catalyst for the company and patients.
FOLLOW THE EVENT
What happens next?
Explore the event, review its rules, and share your prediction on OdinSignal.
Explore the prediction market →Virtual credits only. No cash value.More from the Journal
Summit Therapeutics’ ivonescimab receives FDA PDUFA goal date of Nov 14 2026
Summit Therapeutics’ ivonescimab (HARMONi) BLA has a FDA PDUFA goal action date of November 14 2026 for non‑small cell lung cancer.
Read article →OPEC to Hold 42nd Ministerial Meeting on 29 November 2026
OPEC and non‑OPEC participating countries will convene on 29 Nov 2026 for the 42nd Ministerial Meeting, reaffirming the current crude‑oil production framework.
Read article →U2’s 16th Studio Album ‘Carnaval De Luz’ Set for November 13, 2026 Release
Island Records confirms U2’s new album ‘Carnaval De Luz’ will drop on November 13, 2026, marking their first studio album of new material in nine years.
Read article →Prediction markets express uncertainty, not established outcomes. OdinSignal uses virtual credits with no cash value.